Opinion|Videos|October 21, 2024
The Continued Evolution of Photodynamic Therapy
Author(s)Anthony M. Rossi, MD, FAAD, FACMS
Key Takeaways
- Advancements in photosensitizers and light delivery systems are expected to enhance PDT efficacy and reduce side effects in dermatology.
- Emerging studies focus on optimizing PDT for non-melanoma skin cancers, acne, and inflammatory skin diseases.
Anthony M. Rossi, MD, shares their perspective on the future evolution of photodynamic therapy (PDT) in dermatology practices and discusses emerging data or studies that will be crucial for dermatologists to stay informed about.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your opinion, how will the use of PDT continue to involve in dermatology practices?
- What new emerging PDT data or studies will be most important for dermatologists to familiarize themselves with?
Advertisement
Related to this article
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis
2
Hidradenitis Suppurativa Claims Data: Sex Parity and Rural Care Gaps
3
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
4
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
5